MK-677 vs Ipamorelin
A comparison of MK-677 and Ipamorelin as growth hormone secretagogues, covering oral vs. injectable administration, half-life, GH pulse patterns, and research contexts.
A comparison of MK-677 and Ipamorelin as growth hormone secretagogues, covering oral vs. injectable administration, half-life, GH pulse patterns, and research contexts.
Overview
MK-677 and Ipamorelin are both ghrelin receptor agonists studied for growth hormone secretagogue effects, but they differ substantially in administration route, half-life, and GH pulse pattern. MK-677 is an orally active small molecule, while Ipamorelin is a peptide requiring subcutaneous injection, and these differences define most protocol comparisons between them.
Mechanism Comparison
Both compounds act through the GHSR-1a receptor to stimulate GH release. MK-677 is noted for its long half-life (approximately 24 hours), which produces a sustained elevation in GH and IGF-1 levels rather than discrete pulses. Ipamorelin has a shorter half-life (~2 hours) and is more typically discussed in pulsatile dosing protocols intended to mimic natural GH release timing.
Dosing and Protocol Comparison
MK-677 is typically studied at once-daily oral doses of 10–25 mg, making compliance straightforward. Ipamorelin requires multiple daily injections for pulsatile protocols, often paired with CJC-1295 to amplify the GH signal. Researchers comparing the two often frame MK-677 as more convenient but less controllable, and Ipamorelin as more precise in pulse timing but more demanding in administration frequency.
Evidence Comparison
MK-677 has a meaningful published clinical evidence base including long-duration studies in older adults and GH-deficient populations. Ipamorelin's evidence base is thinner in human studies but well-characterized at the receptor selectivity level. For research purposes, MK-677 offers more published data; Ipamorelin offers more protocol flexibility and selectivity advantage.